Furthermore, patients with cirrhosis exhibit reduced hepatic insulin clearance and increased diversion of insulin from the portal to the systemic circulation (7), thus contributing to insulin resistance and the progression of MASLD. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.